Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

Author information

Affiliations

  • 1. Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France.
      Authors
    • Garciaz S 1
    • Berton G 1
    • Hospital MA 1
    • Saillard C 1
    • Hicheri Y 1
    • Vey N 1
    (6 authors)
  • 2. Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France.
      Authors
    • Guille A 2
    • Adélaïde J 2
    • Birnbaum D 2
    (3 authors)
  • 3. Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
      Authors
    • Mozziconacci MJ 3
    (1 author)
  • 4. Epigenetic Factors in Normal and Malignant Hematopoiesis, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France.
      Authors
    • Duprez E 4
    (1 author)
  • 5. Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
      Authors
    • Récher C 5
    (1 author)
    • Show all (6)

ORCIDs linked to this article

Leukemia & Lymphoma, 08 Feb 2024, 65(5):700-703
https://doi.org/10.1080/10428194.2024.2312430 PMID: 38329727 

Abstract 

No abstract provided.

Full text links 

Read article at publisher's site: https://doi.org/10.1080/10428194.2024.2312430

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.